Study guide
11.3 Antimicrobial Resistance Genotyping
ASCP Molecular Biology Technologist MB
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Strategy
1.1 ASCP MB Exam Structure, Eligibility Routes & Policies 1.2 Computer Adaptive Testing (CAT) & Scoring Mechanics 1.3 Blueprint Navigation & Preparation Strategy
2 Nucleic Acid Chemistry & Molecular Structure
2.1 DNA Structure, Nitrogenous Bases & Thermodynamic Stability 2.2 RNA Types, Secondary Structure & Chemical Lability 2.3 Chromatin Organization, Histone Modifications & DNA Methylation
3 Central Dogma, Genome Organization & Cytogenetics
3.1 DNA Replication Machinery & Enzymology 3.2 Transcription, Translation & Genetic Code 3.3 Mutations, Polymorphisms & Chromosomal Aberrations
4 Biochemical Reagents & Enzymes
4.1 DNA Polymerases, Reverse Transcriptases & Proofreading 4.2 Restriction Endonucleases, Ligases & Nucleases 4.3 Reaction Buffers, Cations & Master Mix Additives
5 Nucleic Acid Isolation & Purification
5.1 Organic & Inorganic Extraction Chemistries 5.2 Solid-Phase Silica Columns & Magnetic Bead Isolation 5.3 Specimen-Specific Lysis & Challenging Matrices
6 Nucleic Acid Quantification & Electrophoresis
6.1 UV Spectrophotometry & Fluorometry 6.2 Agarose & Polyacrylamide Gel Electrophoresis 6.3 Capillary Electrophoresis & Microfluidic Bioanalyzers 6.4 Mass Spectrometry (MALDI-TOF) in Molecular Diagnostics
7 PCR Principles & Primer Design Optimization
7.1 Conventional PCR Thermodynamics & Cycling Kinetics 7.2 Primer Design Criteria, Melting Temp & Secondary Structures 7.3 PCR Inhibition, Facilitators & Troubleshooting
8 Advanced Amplification Technologies
8.1 Real-Time qPCR Probe Chemistries & Fluorescent Dyes 8.2 qPCR Quantification (Standard Curve, ΔΔCt) & Dissociation Melt Curve Analysis 8.3 Digital PCR (dPCR), Droplet Partitioning & Poisson Absolute Quantification 8.4 Isothermal & Target Multiplex Amplification
9 DNA Sequencing Technologies
9.1 Sanger Dideoxy Sequencing & Electropherogram Interpretation 9.2 NGS Library Preparation, Fragmentation & Target Enrichment 9.3 Massively Parallel NGS Platforms & Chemistries 9.4 NGS Quality Metrics, Coverage Depth & Bioinformatics
10 Hybridization, Blotting & Cytogenetic Assays
10.1 Southern, Northern & Dot Blot Chemistries 10.2 Fluorescence In Situ Hybridization (FISH) & CISH 10.3 Microarrays & Array Comparative Genomic Hybridization (aCGH)
11 Molecular Infectious Disease Diagnostics
11.1 Quantitative Viral Load Monitoring (HIV-1, HCV, HBV, CMV) 11.2 Qualitative Multiplex Syndromic Pathogen Panels 11.3 Antimicrobial Resistance Genotyping 11.4 Molecular Epidemiology & Pathogen Typing
12 Molecular Oncology & Hematopathology
12.1 Hematologic Malignancies & Translocation Assays 12.2 Solid Tumor Somatic Driver Mutations 12.3 Microsatellite Instability & DNA Mismatch Repair 12.4 Liquid Biopsy, ctDNA & Minimal Residual Disease
13 Medical Genetics, Pharmacogenomics & Identity Testing
13.1 Single-Gene Mendelian Disorders & CFTR Testing 13.2 Trinucleotide Repeat Expansion Disorders 13.3 Clinical Pharmacogenomics (PGx) Core Alleles 13.4 Human Identity Testing & Post-Transplant Chimerism
14 Quality Assurance, Controls & Method Validation
14.1 Quality Assurance Controls & Reference Materials 14.2 Clinical Method Validation & Performance Characteristics 14.3 Quality Management, Proficiency Testing & Competency
15 Laboratory Operations, Safety & Clinical Variant Reporting
15.1 Physical Facility Design & Unidirectional Workflow 15.2 Laboratory Biosafety, Chemical Hygiene & Waste 15.3 Clinical Calculations, ACMG Variant Classification & HGVS
11.3 Antimicrobial Resistance Genotyping
Key Takeaways Explain This Topic AI
Antimicrobial resistance genotyping identifies specific genetic determinants encoding altered drug targets, enzymatic drug inactivators, efflux systems, or metabolic bypass pathways.
Methicillin resistance in staphylococci is mediated by mecA or mecC on the SCCmec element encoding low-affinity PBP2a, with SCCmec-orfX junction PCR utilized for rapid MRSA screening.
Vancomycin resistance in enterococci involves substituting cell-wall peptidoglycan precursors from D-Ala-D-Ala to D-Ala-D-Lac (vanA, vanB) or D-Ala-D-Ser (intrinsic vanC).
Gram-negative beta-lactamases include Ambler Class A ESBLs and KPC carbapenemases, Class B zinc-dependent metallo-beta-lactamases (NDM, VIM, IMP), Class C AmpC cephalosporinases, and Class D OXA carbapenemases.
Mycobacterium tuberculosis multi-drug resistance (MDR-TB) is genotyped by identifying mutations in the 81-bp rpoB rifampin resistance-determining region alongside katG and inhA promoter mutations for isoniazid resistance.
Last updated: August 2026
11.3 Antimicrobial Resistance Genotyping
Quick Summary: Antimicrobial resistance (AMR) genotyping bypasses the 24- to 48-hour incubation lag of conventional phenotypic broth microdilution by directly amplifying and detecting the specific genes, single-nucleotide polymorphisms (SNPs), or mobile genetic elements that confer drug resistance. Key clinical testing paradigms encompass methicillin resistance in staphylococci ( mecA , mecC ) , vancomycin resistance in enterococci ( vanA , vanB , vanC ) , Gram-negative β \beta β -lactamases (Ambler Classes A–D including bla KPC, bla NDM, bla OXA-48, bla CTX-M) , plasmid-mediated colistin resistance ( mcr-1 ) , and multi-drug resistant Mycobacterium tuberculosis ( rpoB , katG , inhA ) . Understanding the molecular mechanisms of target modification, enzymatic hydrolysis, and genetic mobilization is essential for accurate clinical interpretation and ASCP MB exam success.
1. Gram-Positive Resistance Genotyping +---------------------------------------------------------------------------------------------------------+
- | GRAM-POSITIVE RESISTANCE GENOTYPES & MECHANISMS |
- +---------------------+-------------------+-----------------------------------+---------------------------+
- | Organism / Drug | Resistance Gene(s)| Biochemical Mechanism of Action | Clinical & Diagnostic |
- | Class | | | Considerations |
- +---------------------+-------------------+-----------------------------------+---------------------------+
- | ***S. aureus*** / | ***mecA*** / | Encodes altered **PBP2a (PBP2')** | Carried on mobile |
- | Staphylococci | ***mecC*** | transpeptidase; exceptionally low | **SCC*mec*** cassette. |
- | (Methicillin / | | affinity for all $\beta$-lactams | *SCCmec-orfX* junction PCR|
- | Oxacillin / Cefoxitin) | except 5th-gen cephalosporins. | used for nasal screening. |
- +---------------------+-------------------+-----------------------------------+---------------------------+
- | ***Enterococcus*** | ***vanA*** | Reprograms peptidoglycan precursor| **High-level inducible** |
- | species | (Tn1546) | from D-Ala-D-Ala to **D-Ala-D-Lac**;| resistance to **both** |
- | (Vancomycin / | | 1,000-fold reduced vancomycin bind| vancomycin & teicoplanin. |
- | Glycopeptides) +-------------------+-----------------------------------+---------------------------+
- | | ***vanB*** | Synthesizes **D-Ala-D-Lac**; | Inducible resistance to |
- | | | activated by vancomycin only | vancomycin; susceptible to|
- | | | | teicoplanin *in vitro*. |
- | +-------------------+-----------------------------------+---------------------------+
- | | ***vanC1*** / | Synthesizes **D-Ala-D-Ser** | **Intrinsic low-level** |
- | | ***vanC2/3*** | precursors (low-affinity binding) | non-transferable resistance|
- | | | | in *E. gallinarum/casseli*|
- +---------------------+-------------------+-----------------------------------+---------------------------+
- Methicillin Resistance in Staphylococcus aureus (MRSA)
The mecA / mecC Mechanism: Methicillin resistance is mediated by acquisition of the mecA gene (or its divergent homologue mecC ), located on the mobile genomic island Staphylococcal Cassette Chromosome mec ( SCC mec ). The gene encodes an alternative 78 kDa 78\text{ kDa} 78 kDa penicillin-binding protein, PBP2a (or PBP2') , whose active-site transpeptidase domain possesses exceptionally low binding affinity for virtually all β \beta β -lactam antibiotics (penicillins, cephalosporins, carbapenems), allowing peptidoglycan cross-linking to proceed unimpeded.
SCCmec-orfX Junction PCR for MRSA Nasal Surveillance:
Rapid MRSA nasal screening assays utilize primers targeting the junction between the right extremity of the integrated SCC mec cassette and the conserved chromosomal integration site ( orfX ) of S. aureus .
The "Empty Cassette" Diagnostic Pitfall: Occasionally, a methicillin-susceptible S. aureus (MSSA) strain excises the mecA structural gene but retains a remnant fragment of the SCC mec right extremity inserted in orfX . A junction-only PCR assay will yield a false-positive MRSA result . Advanced molecular assays avoid this by utilizing dual-target triplex PCR that simultaneously confirms the SCCmec-orfX junction AND the presence of the structural mecA/mecC and S. aureus -specific nuc or spa genes. MRSA SCCmec-orfX JUNCTION & EMPTY CASSETTE
True MRSA Cassette:
- --[ S. aureus Chromosome (orfX) ]===[ SCCmec Right Extremity ]---[ mecA Gene ]---> (TRUE POSITIVE)
- |--- Junction PCR Primer Target ---|
"Empty Cassette" MSSA Variant:
- --[ S. aureus Chromosome (orfX) ]===[ Remnant SCCmec Extremity ]-----------------> (FALSE POSITIVE MRSA!)
- |--- Junction PCR Still Amplifies! ---|
- Vancomycin Resistance in Enterococcus (VRE)
Peptidoglycan Target Remodeling: Vancomycin binds with high affinity to the terminal D-Alanyl-D-Alanine (D-Ala-D-Ala) dipeptide of cell-wall lipid II precursors via 5 hydrogen bonds, physically blocking transglycosylase and transpeptidase enzymes from building the peptidoglycan wall.
The vanA & vanB Operons: VRE strains carry a multi-gene regulatory operon ( vanR-vanS-vanH-vanA-vanX-vanY-vanZ ) that senses glycopeptides and synthesizes modified D-Alanyl-D-Lactate (D-Ala-D-Lac) termini. Replacing the terminal amide hydrogen with an ester oxygen eliminates a critical hydrogen bond and introduces electrostatic repulsion, reducing vancomycin binding affinity by 1,000-fold .
Clinical Distinction of vanC : Strains of Enterococcus gallinarum ( vanC1 ) and Enterococcus casseliflavus ( vanC2/vanC3 ) possess intrinsic, chromosomal, non-transferable resistance via D-Alanyl-D-Serine (D-Ala-D-Ser) synthesis. These organisms exhibit low-level resistance (vancomycin MIC 4 – 32 μ g/mL \text{MIC } 4–32\;\mu\text{g/mL} MIC 4–32 μ g/mL ) and do not represent an infection control outbreak emergency like plasmid-borne vanA/vanB VRE.
2. Gram-Negative Resistance & β \beta β -Lactamase Classification
Gram-negative β \beta β -lactamases hydrolyze the four-membered β \beta β -lactam ring, rendering antibiotics inactive. They are classified structurally via the Ambler Molecular Classification based on active-site amino acid homology. +---------------------------------------------------------------------------------------------------------+
- | AMBLER MOLECULAR CLASSIFICATION OF BETA-LACTAMASES |
- +--------+-------------------+-----------------------+-------------------+--------------------------------+
- | Ambler | Active Site | Representative | Hydrolysis | Inhibitor Profile |
- | Class | Catalytic Group | Resistance Genes | Substrate Spectrum| |
- +--------+-------------------+-----------------------+-------------------+--------------------------------+
- | **A** | **Active-Site** | ***bla*TEM**, | Penicillins, | **Inhibited by:** Clavulanic |
- | | **Serine** | ***bla*SHV**, | early/extended | acid, Tazobactam, Avibactam, |
- | | | ***bla*CTX-M** (ESBLs)| cephalosporins, | Vaborbactam. |
- | | | ***bla*KPC** | & carbapenems | (*bla*KPC hydrolyzes |
- | | | (Carbapenemase) | (*bla*KPC only). | carbapenems). |
- +--------+-------------------+-----------------------+-------------------+--------------------------------+
- | **B** | **Divalent Zinc** | ***bla*NDM** (New | **ALL** $\beta$-lactams| **NOT inhibited by:** Avibactam|
- | | **Cofactor** | Delhi), ***bla*VIM**, | and carbapenems | or Clavulanic acid. |
- | | **(Metallo-MBL)** | ***bla*IMP** | **EXCEPT** | **Inhibited by:** EDTA & |
- | | | | **Aztreonam**. | divalent metal chelators. |
- +--------+-------------------+-----------------------+-------------------+--------------------------------+
- | **C** | **Active-Site** | ***bla*AmpC**, | Penicillins, | **Resistant to:** Clavulanate |
- | | **Serine** | ***bla*CMY**, | 1st-3rd gen | and Tazobactam. |
- | | (Cephalosporinase)| ***bla*FOX**, | cephalosporins, | Susceptible to: **Cefepime** |
- | | | ***bla*DHA** | cephamycins (fox).| and Carbapenems. |
- +--------+-------------------+-----------------------+-------------------+--------------------------------+
- | **D** | **Active-Site** | ***bla*OXA-48-like**, | Oxacillin, | **Poorly inhibited** by |
- | | **Serine** | ***bla*OXA-23**, | penicillins, and | clavulanate; |
- | | (Oxacillinases) | ***bla*OXA-24/40** | variable low-level| variable inhibition by |
- | | | | carbapenems. | Avibactam. |
- +--------+-------------------+-----------------------+-------------------+--------------------------------+
- Key Gram-Negative Resistance Determinants
Extended-Spectrum β \beta β -Lactamases (ESBLs): Predominantly bla CTX-M variants (such as bla CTX-M-14 and bla CTX-M-15). Hydrolyze third-generation cephalosporins (ceftriaxone, ceftazidime, cefotaxime) and monobactams (aztreonam), but are inhibited by β \beta β -lactamase inhibitors (clavulanate, tazobactam).
Klebsiella pneumoniae Carbapenemase ( bla KPC): Ambler Class A serine carbapenemase carried on Tn4401 transposons. Hydrolyzes all penicillins, cephalosporins, and carbapenems (ertapenem, imipenem, meropenem). Inhibited by novel non- β \beta β -lactam β \beta β -lactamase inhibitors like avibactam and vaborbactam .
Metallo- β \beta β -Lactamases (MBLs - bla NDM, bla VIM, bla IMP): Ambler Class B enzymes requiring divalent zinc ( Zn 2 + \text{Zn}^{2+} Zn 2 + ) ions in their active site to coordinate and hydrolyze the β \beta β -lactam carbonyl bond.
High-Yield ASCP MB Rule: MBLs hydrolyze all β \beta β -lactams and carbapenems EXCEPT monobactams (aztreonam) .
They are refractory to all classic and modern β \beta β -lactamase inhibitors (clavulanate, tazobactam, avibactam, vaborbactam, relebactam). They are inhibited in vitro only by metal-chelating agents such as EDTA or dipicolinic acid.
Plasmid-Mediated Colistin Resistance ( mcr-1 to mcr-10 ):
Colistin (polymyxin E) is a positively charged cationic peptide that binds electrostatically to the negatively charged phosphate groups of Lipid A in Gram-negative lipopolysaccharide (LPS).
The mcr-1 gene encodes a membrane-bound phosphoethanolamine transferase that transfers a phosphoethanolamine moiety onto Lipid A. This neutralizes the negative surface charge of LPS, preventing colistin binding and conferring resistance.
3. Mycobacterial & Viral Drug Resistance Genotyping +---------------------------------------------------------------------------------------------------------+
- | MYCOBACTERIAL & VIRAL RESISTANCE GENOTYPES |
- +---------------------+-------------------+-----------------------------------+---------------------------+
- | Pathogen | Resistance Target | Molecular Mechanism / Codon Change| Clinical Implication |
- +---------------------+-------------------+-----------------------------------+---------------------------+
- | ***Mycobacterium*** | ***rpoB*** | Mutations in **81-bp RRDR** | **Rifampin resistance;** |
- | ***tuberculosis*** | (RNA Pol $\beta$) | (Codons 507–533; e.g., **S531L**) | surrogate for **MDR-TB**. |
- | +-------------------+-----------------------------------+---------------------------+
- | | ***katG*** | Catalase-peroxidase mutation | **High-level Isoniazid** |
- | | | (e.g., **S315T**) | (INH) resistance. |
- | +-------------------+-----------------------------------+---------------------------+
- | | ***inhA*** | Promoter mutation (e.g., **C-15T**)| **Low-level INH** + |
- | | | upregulating enoyl-ACP reductase | **Ethionamide** cross-res.|
- | +-------------------+-----------------------------------+---------------------------+
- | | ***gyrA / gyrB*** | Quinolone resistance region (QRDR)| Fluoroquinolone resistance|
- +---------------------+-------------------+-----------------------------------+---------------------------+
- | **HIV-1** | **Reverse Trans-**| **M184V** (NRTI resistance) | High-level 3TC/FTC resist.|
- | | **criptase** | **K103N** (NNRTI resistance) | Efavirenz/Nevirapine resist|
- | +-------------------+-----------------------------------+---------------------------+
- | | **Integrase** | **Q148H/R/K**, **N155H** | INSTI resistance |
- +---------------------+-------------------+-----------------------------------+---------------------------+
- | **CMV** | ***UL97*** kinase | **M460V/I**, **H520Q**, **C592G** | Ganciclovir resistance; |
- | | | (Prevents monophosphorylation) | Foscarnet remains active. |
- | +-------------------+-----------------------------------+---------------------------+
- | | ***UL54*** DNA pol| DNA polymerase catalytic mutations| **Cross-resistance to** |
- | | | | **ganciclovir & foscarnet**|
- +---------------------+-------------------+-----------------------------------+---------------------------+
- Mycobacterium tuberculosis (MDR-TB and XDR-TB)
Multidrug-Resistant Tuberculosis (MDR-TB): Defined as M. tuberculosis strains resistant to at least the two primary first-line antitubercular drugs: Rifampin (RIF) and Isoniazid (INH) .
Extensively Drug-Resistant Tuberculosis (XDR-TB): Defined as MDR-TB plus resistance to any fluoroquinolone (e.g., levofloxacin, moxifloxacin) and at least one additional Group A drug (e.g., bedaquiline or linezolid).
Molecular Diagnostic Targets:
rpoB (Rifampin): > 95 % >95\% > 95% of all rifampin-resistant strains harbor mutations within an 81-base pair Rifampin Resistance Determining Region (RRDR) (codons 507 to 533) of the RNA polymerase β \beta β -subunit. Because > 90 % >90\% > 90% of rifampin-resistant isolates are also resistant to isoniazid, detection of an rpoB mutation serves as an immediate molecular surrogate for MDR-TB.
katG (Isoniazid - High Level): Isoniazid is a prodrug requiring activation by the mycobacterial catalase-peroxidase enzyme encoded by katG . The Ser315Thr (S315T) missense mutation impairs prodrug activation, causing high-level INH resistance.
inhA Promoter (Isoniazid - Low Level & Cross-Resistance): Mutations in the ribosome-binding/promoter region of inhA (e.g., C-15T ) cause overexpression of the target enoyl-ACP reductase enzyme. This confers low-level INH resistance and concurrent cross-resistance to the second-line drug ethionamide .
4. Genotype-to-Phenotype Discrepancies & Limitations
While molecular resistance testing provides same-day results, technologists must understand the biological causes of genotype-to-phenotype discrepancies:
Unexpressed or Downregulated Genes: Detection of a resistance gene (e.g., bla TEM or ampC ) does not guarantee high-level phenotypic resistance if promoter mutations prevent robust transcription or if the gene is a non-functional pseudogene.
Alternative Resistance Mechanisms: The absence of a specific target gene (e.g., lack of bla KPC) does not guarantee susceptibility; carbapenem resistance can result from outer membrane porin loss (e.g., ompK35/ompK36 deletion) coupled with hyperproduced AmpC or ESBL enzymes.
Novel Uncharacterized Mutations: Targeted assays only detect known, probed mutations. Novel single-nucleotide variants in enzyme active sites will be missed unless full-gene Next-Generation Sequencing (NGS) is employed.